Haematopoietic stem cell transplantation in haemophagocytic lymphohistiocytosis

Haemophagocytic lymphohistiocytosis (HLH) poses major therapeutic challenges, and the primary inherited form, familial haemophagocytic lymphohistiocytosis (FHL), is usually fatal. We evaluated, including Cox regression analysis, survival in 86 children (29 familial) that received HLH‐94‐therapy (etoposide, dexamethasone, ciclosporin) followed by allogeneic stem cell transplantation (SCT) between 1995 and 2000. The overall estimated 3‐year‐survival post‐SCT was 64% [confidence interval (CI) = ±10%] (n = 86); 71 ± 18% in those patients with a matched related donor (MRD, n = 24), 70 ± 16% with a matched unrelated donor (MUD, n = 33), 50 ± 24% with a family haploidentical donor (haploidentical, n = 16), and 54 ± 27% with a mismatched unrelated donor (MMUD, n = 13). After adjustment for potential confounding factors, estimated odds ratios (OR) for mortality were 1·93 (CI =0·61–6·19) for MUD, 3·31 (1·02–10·76) for haploidentical, and 3·01 (0·91–9·97) for MMUD, compared with MRD. In children with active disease after 2‐months of therapy (n = 43) the OR was 2·75 (1·26–5·99), compared with inactive disease (n = 43). In children with active disease at SCT (n = 37), the OR was 1·80 (0·80–4·06) compared with inactive disease (n = 49), after adjustment for disease activity at 2‐months. Mortality was predominantly transplant‐related. Most HLH patients survived SCT using MRD or MUD, and survival with partially mismatched donors was also acceptable. Patients that responded well to initial pretransplant‐induction therapy fared best, but some persisting HLH activity should not automatically preclude performing SCT.

[1]  G. Janka,et al.  Familial hemophagocytic lymphohistiocytosis , 1983, European Journal of Pediatrics.

[2]  A. Fischer,et al.  Munc13-4 Is Essential for Cytolytic Granules Fusion and Is Mutated in a Form of Familial Hemophagocytic Lymphohistiocytosis (FHL3) , 2003, Cell.

[3]  R. Egeler,et al.  Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. , 2002, Blood.

[4]  A. Fischer,et al.  Functional consequences of perforin gene mutations in 22 patients with familial haemophagocytic lymphohistiocytosis , 2002, British journal of haematology.

[5]  H. Takada,et al.  Perforin defects of primary haemophagocytic lymphohistiocytosis in Japan , 2002, British journal of haematology.

[6]  R. Clementi,et al.  Six novel mutations in the PRF1 gene in children with haemophagocytic lymphohistiocytosis , 2001, Journal of medical genetics.

[7]  Marion E. Schneider,et al.  Spectrum of perforin gene mutations in familial hemophagocytic lymphohistiocytosis. , 2001, American journal of human genetics.

[8]  A. Fischer,et al.  Perforin gene defects in familial hemophagocytic lymphohistiocytosis. , 1999, Science.

[9]  N. Kröger,et al.  Improved outcome in haemophagocytic lymphohistiocytosis after bone marrow transplantation from related and unrelated donors: a single‐centre experience of 12 patients , 1999, British journal of haematology.

[10]  J. Henter,et al.  Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunochemotherapy. Histiocyte Society. , 1999, Blood.

[11]  M. Hirosawa,et al.  Allogeneic hematopoietic stem cell transplantation for patients with hemophagocytic syndrome (HPS) in Japan , 1999, Bone Marrow Transplantation.

[12]  G. Kögler,et al.  Unrelated 5/6-locus matched umbilical cord blood transplantation in a 23-month-old child with hemophagocytic lymphohistiocytosis , 1998, Bone Marrow Transplantation.

[13]  J. Henter,et al.  Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis. , 1998, Hematology/oncology clinics of North America.

[14]  M. Aricò,et al.  Familial hemophagocytic lymphohistiocytosis. Primary hemophagocytic lymphohistiocytosis. , 1998, Hematology/oncology clinics of North America.

[15]  M. Steinbuch,et al.  Successful correction of hemophagocytic lymphohistiocytosis with related or unrelated bone marrow transplantation. , 1997, Blood.

[16]  R. Egeler,et al.  HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society. , 1997, Medical and pediatric oncology.

[17]  J. Henter,et al.  Neuropathologic findings and neurologic symptoms in twenty-three children with hemophagocytic lymphohistiocytosis. , 1997, The Journal of pediatrics.

[18]  A. Fischer,et al.  Frequency and severity of central nervous system lesions in hemophagocytic lymphohistiocytosis. , 1997, Blood.

[19]  A. Fischer,et al.  Treatment of familial hemophagocytic lymphohistiocytosis with bone marrow transplantation from HLA genetically nonidentical donors. , 1997, Blood.

[20]  A. Fischer,et al.  Hemophagocytic lymphohistiocytosis. Report of 122 children from the International Registry. FHL Study Group of the Histiocyte Society. , 1996, Leukemia.

[21]  P. Ljungman,et al.  Allogeneic bone marrow transplantation for hemophagocytic lymphohistiocytosis in Sweden. , 1995, Bone marrow transplantation.

[22]  F. Ledeist,et al.  Treatment of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins, steroids, and cyclosporin A. , 1993, Blood.

[23]  J. Andersson,et al.  Familial hemophagocytic lymphohistiocytosis and viral infections , 1993, Acta paediatrica.

[24]  F. Ledeist,et al.  Treatment of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins, steroids, and cyclosporin A , 1993 .

[25]  J. Henter,et al.  Cerebromeningeal haemophagocytic lymphohistiocytosis , 1992, The Lancet.

[26]  C. Griscelli,et al.  Treatment of hemophagocytic lymphohistiocytosis with chemotherapy and bone marrow transplantation: a single-center study of 22 cases. , 1991, Blood.

[27]  A. Öst,et al.  Incidence in Sweden and Clinical Features of Familial Hemophagocytic Lymphohistiocytosis , 1991, Acta paediatrica Scandinavica.

[28]  A. Öst,et al.  DIAGNOSTIC GUIDELINES FOR HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS , 1991 .

[29]  J. Armitage,et al.  The use of recombinant human granulocyte-macrophage colony stimulating factor for the treatment of delayed engraftment following high dose therapy and autologous hematopoietic stem cell transplantation for lymphoid malignancies. , 1991, Bone marrow transplantation.

[30]  V. Vitale,et al.  Familial haemophagocytic lymphohistiocytosis treated with allogeneic bone marrow transplantation. , 1991, Bone marrow transplantation.

[31]  T. Yoshihara,et al.  Allogeneic Bone Marrow Transplantation for Familial Erythrophagocytic Lymphohistiocytosis, with High Dose VP16-Containing Conditioning Regimen. , 1990, Leukemia & lymphoma.

[32]  M. List,et al.  The measurement of performance in childhood cancer patients , 1987, Cancer.

[33]  O. Söder,et al.  SUCCESSFUL INDUCTION WITH CHEMOTHERAPY INCLUDING TENIPOSIDE IN FAMILIAL ERYTHROPHAGOCYTIC LYMPHOHISTIOCYTOSIS , 1986, The Lancet.

[34]  G. Leverger,et al.  Allogeneic bone marrow transplantation for erythrophagocytic lymphohistiocytosis. , 1986, The Journal of pediatrics.

[35]  A. Fischer,et al.  Treatment of four patients with erythrophagocytic lymphohistiocytosis by a combination of epipodophyllotoxin, steroids, intrathecal methotrexate, and cranial irradiation. , 1985, Pediatrics.